Reference: 1. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart
Study): a randomized, open-label, blinded endpoint morbidity-mortality study. The Lancet 2007;369:1431-1439. 2. Jikei Heart Study Available from: URL:http://www.escardio.org/congresses/
World_Congress_Cardiology_2006/Documents/Dahlof-Mochizuki-FP3419-slide-resource-wcc06.pdf. S3 Zomevek
®
80, 160. Reg No:43/7.1.3/0036,7. Each tablet contains 80/160 mg valsar-
tan. S3 Co-Zomevek
®
80/12,5, 160/12.5, 160/25. Reg No: 43/7.1.3/0080,1,2. Each tablet contains 80/160 mg valsartan and 12.5/25 mg hydrochlorothiazide. Marketed by Sandoz SA
(Pty) Ltd. 72 Steel Road, Spartan, Kempton Park, 1619. Tel: 011 929 9000, Fax: 011 929 9296.
Reg No. 1990/001979/07. SAN 1627 09 2010
For further information refer to the package insert
a Novartis company
Beyond Hypertension control
Treatment must consider not only aggressive blood
pressure control, but also which blood pressure
molecule is the best choice to prevent outcomes
1,2
